Tagged with EY

USA Tatsuya Kaihara, head of US operations for Japanese eyecare specialist Santen, describes his excitement at bringing two new ophthalmic advancements to the US market, the similarities, differences, and synergies of Japanese and American innovation, and the challenges of building a unified corporate culture.   This is a very exciting moment…

Roundup A roundup of the latest from the Middle East & Africa region, including Turkey’s debt to US pharma; deals between Saudi SPIMACO and Janssen, Abu Dhabi Mubadala and Germany’s Evotec, and Turkey’s Abdi Ibrahim and Swiss OM Pharma; and whether poorer countries in Africa can truly expect equal access to…

Turkey The COVID-19 pandemic continues to spread rapidly across the globe amid critical supply shortages of medical devices and medicines. The rapid spread of the virus, on the one hand, threatens supply chains and causes shortages, on the other hand, it also strengthens global solidarity.   Brands from different sectors make an…

Global Charlotte Kremer is head of medical affairs for Astellas Pharma and serves as the president of the Medical Affairs Professional Society. At eyeforpharma Barcelona by Reuters Events 2020, a virtual conference held between March 31 and April 3, Kremer spoke on the evolving strategic role of medical affairs in driving…

China 2019 was a landmark year for the Chinese healthcare industry.* Since the publication of the ‘Healthy China 2030’ blueprint in 2016 by the Chinese government, the entire sector has been virtually turned upside down. Against the warm backdrop of regulatory support, a series of policy changes were unveiled in the…

Coronavirus The 2019 Wuhan coronavirus outbreak has seen a surge in demand for protective masks as publics across the world seek to protect themselves from infection. Manufacturers of the masks have seen their stocks boom, but supply is outstripping demand and hoarding practices may leave healthcare professionals on the frontline of…

Pharma Legal Handbook The low-down on the situation regarding biosimilars & biologics in Turkey. Prepared in association with Moroğlu Arseven, a leading Turkish law firm, this is an extract from The Pharma Legal Handbook: Turkey, available to purchase here for GBP 75.   1. Are biosimilar medicines considered the same as generic medicines in…

Pharma Legal Handbook The ins and outs of localization in Turkey. Prepared in association with Moroğlu Arseven, a leading Turkish law firm, this is an extract from The Pharma Legal Handbook: Turkey, available to purchase here for GBP 75.   1. Are there any rules or regulations requiring and/or encouraging localization in your country?…

Pharma Legal Handbook Keen to learn more about orphan drugs & rare diseases in Turkey? Read on! Prepared in association with Moroğlu Arseven, a leading Turkish law firm, this is an extract from The Pharma Legal Handbook: Turkey, available to purchase here for GBP 75.   1. What is the definition of Rare Diseases…

Merck Since we last met with Paolo Carli in 2013, he has been given greater responsibilities within Merck and is now Head of Middle East, Africa, Turkey, Russia, and CIS countries for the healthcare business. Paolo discusses the logic behind being assigned such a vast region to manage, Merck’s strategy for…

Turkey There is perhaps no Turkish company in the healthcare sector that is more ambitious than Acıbadem. Not only has the private hospital group revolutionized healthcare in Turkey with its advanced facilities, but it has also pursued an ambitious internationalization campaign and even opened a world-class university, to boot.   We…

Turkey Dr Ferhat Farsi, CEO and founding partner of CinnaGen İlaç, shares his experience working for the largest biotech in the MENA region, Turkey’s important role within the global group, and his ambitious plans for the future.   “Having worked for leading Turkish companies for several years … I realized that…